Breakthrough Therapies for Geographic Atrophy Offer Patients Hope at SCRI

Breakthrough Therapies For Geographic Atrophy Offer Patients Hope At SCRI

In the pursuit of providing state-of-the-art care for patients dealing with age-related macular degeneration (AMD) and geographic atrophy (GA), South Carolina Retina Institute (SCRI) is pleased to introduce two groundbreaking therapeutic eye injection treatments: SYFOVRE™ (pegcetacoplan injection) and IZERVAY™ (avacincaptad pegol). Both FDA-approved in 2023, these medications offer hope for individuals suffering from geographic atrophy – a type of advanced dry AMD that can lead to severe vision loss and legal blindness.

Understanding Geographic Atrophy (GA)

Geographic atrophy is a progressive form of dry AMD characterized by the gradual loss of cells in the macula, the central part of the retina responsible for sharp vision. This condition manifests as a patch of dead cells in the macula that expands over time, causing increasing vision loss. GA is a slow and progressive disease that can affect both eyes, posing a significant threat to an individual’s visual health.

SYFOVRE™ and IZERVAY™ as RNA Aptamer Therapeutics

SYFOVRE™ and IZERVAY™ are RNA aptamer therapeutics designed to target chronic conditions like GA that could potentially lead to blindness. SYFOVRE™ was the first FDA-approved treatment for GA, and IZERVAY™ followed suit. These medications represent a significant milestone in treating a previously untreatable disease – aiming to regulate the overactivated part of the immune system in the patient’s eye, a factor contributing to the progression of GA.

Treatment at SCRI

While GA cannot be cured, and damage from lesion growth cannot be reversed, SCRI is currently offering these revolutionary treatments to high-risk individuals acutely threatened by this disease process. This breakthrough in therapeutic options demonstrates our commitment to improving outcomes and preserving vision for those facing the challenges of GA.

Researchers are actively exploring new treatments for GA, including drugs targeting the immune system and gene therapy. SCRI recognizes the importance of ongoing research and continues to stay at the forefront of advancements to provide the best care for our patients. There is hope for slowing the progression of AMD. Recent developments in injectable medications and specially formulated over-the-counter vitamins may aid in slowing the progression of AMD. Organizations and support groups can provide resources on magnification devices, large print materials, and adaptive technologies to empower individuals with AMD to lead more independent lives.

Regular Screenings for Early Detection

As you age, regular visits to your eye doctor for screenings and examinations become crucial in detecting the early signs of AMD. Most people may not realize they have AMD until their vision becomes blurry – underscoring the importance of proactive eye care. The team at South Carolina Retina Institute is dedicated to providing therapeutic treatment options to help prevent or slow down vision loss associated with AMD.

At South Carolina Retina Institute, our experienced Retina Specialists are at the forefront of diagnosing and treating eye conditions. SCRI is dedicated to helping individuals throughout Myrtle Beach and the Grand Strand maintain their eyesight at our offices in Conway and Murrells Inlet. Our compassionate team is committed to providing quality retina care and offering breakthrough therapeutic options like SYFOVRE™ and IZERVAY™ to give hope to those facing geographic atrophy. Contact us today for a consultation and discover how we can help you on your journey to better eye health.